DISSECTING AND EXPLOITING MOLECULAR RECOGNITION AT PROTEIN-PROTEIN INTERFACES

Lead Research Organisation: University of Dundee
Department Name: School of Life Sciences

Abstract

Proteins regulate many of the processes that are crucial for the activity of a living cell. In order to successfully carry out their biological function, proteins often interact in complex with other proteins. The principal subject of the proposed research concerns the development of new approaches to advance our understanding of protein-protein interactions and of how we could disrupt these interactions using the binding of a small molecule. In this project, I focus on studying the binding of small molecules to protein interfaces. I pose the following questions: what features of protein interfaces determine binding and activity (or lack thereof) of a small molecule? Can we modify protein interfaces so that a small molecule can 'stick' to the surface better and better? What can we learn from these new interfaces? How can we use such information to discover new compounds that could function in the cell by binding tightly to these sites? To interrogate protein interfaces, I will first use protein engineering, a technique to generate mutations on a protein by changing amino acids, the building blocks of proteins, from one type to another. I will make mutations in a defined manner, by replacing large amino acids at the protein interface with smaller and smaller ones, hence creating larger and larger cavities. The location and strength of small molecules bound to these engineered pockets will be determined. This will provide useful information to find other protein interfaces that may be functional in living organisms, and that may have the potential to be disrupted using small molecules. Secondly, I will exploit this knowledge further to facilitate identification of small molecules that function by disrupting a protein interface. I will develop new methods to detect small molecules that bind together to adjacent sites of the interface. For this purpose, I will use nuclear magnetic resonance (NMR) spectroscopy, a technique that allows monitoring the hydrogen atoms of small molecules and that can report if these are bound to a protein close to one another. I will also make crystals of the protein in which the interface is accessible to small molecules, and let these molecules react together as they are bound close to each other at the protein surface. Since the structure of a small molecule bound to the protein can be determined directly by shooting X-ray radiations at the protein crystal, a technique called X-ray crystallography, this is a rapid way of identifying any compound that has successfully assembled at the protein interface. The research is important and exciting for the following reasons: 1. Protein interfaces tend to be relatively flat and featureless, as they were not 'evolved' by nature to bind small molecules. The modulation of protein-protein interactions using small molecules is therefore a challenging task, and is at the forefront of molecular recognition. 2. A new scientific horizon is to advance our understanding of biological systems by disrupting pathways and networks in a selective fashion inside the cell. As protein-protein interactions occur widely within the cell, their modulation using small molecules offers an opportunity to interrogate and discover new biology. 3. The disruption of protein-protein complexes offers a novel and general mechanism to develop new medicines. In conclusion, this research has the potential to significantly impact on the way new biology and new drugs will be discovered in the future, with wider benefits to society and exciting opportunities in the fight against disease.

Technical Summary

The overall objective of this fellowship application is to advance our fundamental understanding of molecular recognition at protein interfaces by small organic compounds. The project will employ a unique combination of molecular biology and biophysical studies of protein-ligand interactions to dissect the nature of non-covalent interactions at protein interfaces, and to exploit such knowledge with the goal of aiding small molecule design. I will study the interaction of small peptides and fragment-like compounds (MW < 300 Da) to the tumour suppressor Von Hippel-Lindau (pVHL), a protein which is part of a complex responsible for the degradation of the Hypoxia-Inducible Factor (HIF-1) inside the cell. I will use protein engineering to make larger and larger cavities at the pVHL:HIF-1 interface with the aim to bind small molecule with increasingly higher affinities. I will study the fundamental changes to the recognition of the small molecules in terms of structure (using X-ray crystallography) and thermodynamics (using low c value isothermal titration calorimetry). This information will provide a platform for future studies in the following two directions: 1) to find structurally similar protein interfaces that may be druggable, using computational tools and structural databases; 2) to facilitate discovery of novel small molecules that bind with high affinity and specificity to a protein interface, using intermolecular Nuclear Overhauser Effect to identify fragments binding at adjacent sites by NMR spectroscopy, and Dynamic Combinatorial X-ray Crystallography to assemble fragments together in the presence of a protein crystal, with the aim of selecting the highest affinity compound. Together these studies will provide significant new insights into the principles that govern the modulation of protein-protein interactions using small molecules, and new tools for studying systems of biological importance and therapeutic potential.

Publications

10 25 50

publication icon
Alessio Ciulli (Author) (2014) A novel approach to engineer selectivity of bromodomain chemical probes in ChemMedChem

publication icon
Cipriano A (2020) Targeting epigenetic reader domains by chemical biology. in Current opinion in chemical biology

 
Title Video of the Dundee-Messina project - Ciulli Lab 
Description the video is being used to support the dissemination of the Dundee-Messina project funded by the MIUR programme Messaggeri della Conoscenza 
Type Of Art Film/Video/Animation 
Year Produced 2014 
Impact impact not yet realised - video just published online 
URL https://www.youtube.com/watch?v=JFF7QN22yEI
 
Description 1) VHL-HIF inhibitors. In collaboration with Craig Crews (Yale University), we have discovered first-in-class small molecules that bind the E3 CRL component von-Hippel Lindau protein (VHL) and disrupt its interaction with substrate Hypoxia Inducible Factor alpha subunit (HIFa) (Van Molle et al., Chem. Biol., 2012; Buckley et al., J. Am. Chem. Soc. 2012; Angew. Chem. Int. Ed. 2012). More recently, my laboratory conducted extensive rational design, guided by liganded crystal structures and biophysical binding characterization, to improve the binding affinity and physicochemical properties of the compounds (Galdeano et al., J. Med. Chem 2014). These exciting discoveries and the resulting filed patents have led to the establishment of spin-off company Arvinas in the U.S. and of a Discovery Platform Unit (DPU) in Protein Degradation within GSK. In 2016, we developed and characterized potent and selective VHL as novel chemical probes of the hypoxic signalling pathway has been accepted for publication in Nature Communication. In brief, chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs) activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities and off-target effects. In our article, we report VH298, a potent VHL inhibitor that stabilizes HIF alpha and elicits a hypoxic response via a different mechanism, that is blockade of the VHL:HIF ?lpha protein-protein interaction downstream of HIF alpha hydroxylation by PHD enzymes. We show that VH298 engages with high affinity and specificity with VHL as its only major cellular target, leading to selective on-target accumulation of hydroxylated HIF-alpha in a concentration- and time-dependent fashion in different cell lines, with subsequent upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a high-quality chemical probe of the HIF signaling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signaling. This work is the result of collaboration between my lab and Sonia Rocha (GRE), Doreen Cantrell (CSI) and Kevin Read (DDU) within Dundee SLS. As a result, VH298 is now available to the wide scientific community, and will prove an attractive lead compound for further drug development. The entire structure-activity relationship that led to the identification of VH298 was disclosed later in 2017 in J Med Chem.

2) PROTACs. We have designed molecules based on the discovered VHL ligands, to induce intracellular removal of proteins of interest via the ubiquitin-proteasome system by hijacking and directing proteins to VHL. Such chimaeric molecules (PROTACs) act as chemical degraders of the target as opposed to just inhibitors and more closely phenocopy traditional gene knockdown tools e.g. RNAi. We have recently shown that a compound linking the pan-selective bromo and extraterminal (BET) bromodomain inhibitor JQ1 to our VHL ligand not only induces potent dose- and time-dependent destruction of BET proteins, but crucially is selective for Brd4 over other BET members Brd2 and Brd3, leading to a more limited Brd4-specific transcriptional response when compared to that of pan-inhibitor JQ1 (Zengerle et al., ACS Chem. Biol. 2015). This now provides unprecedented opportunities to study the physiological and therapeutic consequences of intra-BET selective modulation of the drug target Brd4. Two highlights from the Lab published in 2017 have been the first ternary PROTAC crystal structure (published in Nature Chemical Biology) and the first homo-PROTAC inducing an E3 ligase to degrade itself (published n Nature Communications). Our pioneering discoveries in VHL inhibitors and PROTACs have helped to lay the foundation of a new exciting major collaborative agreement with Boehringer Ingelheim on PROTACs, and a recent revolution in approaching targeted protein degradation for drug discovery.

3) Ligandability of CRLs. Using the VHL-HIFa inhibitors as a starting point, we have carried out fundamental analyses of what type of ligands can more effectively probe PPIs and what approaches can best find these molecules (Van Molle et al., Chem. Biol., 2012; Dias et al., ACS Med. Chem Lett., 2014). This research is increasing our understanding of the druggability of PPIs, which helps to intervene effectively and reduce risks associated with tackling such challenging targets.

4) CRL complexes. Using a hybrid approach combining biophysical and structural techniques in innovative ways, and in collaboration with experts in ion-mobility native mass spectrometry (Dr. Djana Matak-Vinkovic, Cambridge and Prof Frank Sobott, Antwerp) and chemoproteomics (Dr Paola Grandi, GSK-Cellzome), we have dissected in increasing level of detail the molecular structure, assembly and interactions of components of complexes and their PTMs within the CRL5-ASB9 (Thomas et al., Biochemistry, 2013) and CRL5-SOCS2 (Bulatov et al., J. Biol. Chem., 2015; Gadd et al., Plos One, 2015).
Exploitation Route by exploiting their potential as chemical tools and therapeutics
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology

URL http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli
 
Description The breakthrough discoveries made by our laboratory and collaborators of potent VHL ligands have led not only to several publications, but also two patents (US 2014356322 and WO 2013106646), and to the establishment of Yale spin-off Arvinas in the US and a Discovery Platform Unit (DPU) within GlaxoSmithKline Stevenage, UK. Such activity represents tangible output of Dr. Ciulli's research in terms of impact, innovation and commercial exploitation. Arvinas and the GSK DPU are pharmaceutical companies both focused on developing small molecule strategies aimed at degrading disease- causing cellular proteins, with a focus in oncology amongst other therapeutic areas. One breakthrough was the design of super-targeted inhibitors, which have exquisite selectivity for honing in on individual BET bromodomains (protein interaction modules that bind acetyl-lysine), without affecting the many other such domains in a cell. The trick was a novel `bump-and-hole' approach that matches the inhibitors to dual features of the target sites (Science, 2014, 346, 638-641). In a further twist, the Ciulli Lab developed a new class of compounds that do not just block BET proteins, but spark a process of degradation, which eventually destroys with exquisite selectivity the cognate protein (ACS Chem Biol, 2015, 10, 1770-1777). This is achieved by means of hetero-bifunctional molecules known as PROteolysis TArgeting Chimeric molecules (PROTACs) that targets the selected protein to the ubiquitin-proteasome degradation pathway using an E3 ligase ligand that the group had previously discovered (J Med Chem, 2014, 57, 8657-8663). Since proteins containing BET bromodomains play crucial roles in many cellular physiological pathways relevant to health and disease, the compounds have exciting potential to accelerate development of therapeutic drugs with minimal side effects and toxicity. Following these discoveries, Dr Ciulli and the University are engaged in confidential discussions to partner with pharmaceutical companies. Dr Ciulli and the UoD have filed two patents relating to the new approaches (patent number WO/2015/079259 http://www.freepatentsonline.com/WO2015079259A3.html; and Patent Application No. GB 1504314.4, Filing Date: March 13, 2015).
First Year Of Impact 2012
Sector Healthcare,Pharmaceuticals and Medical Biotechnology
Impact Types Economic

 
Description BBSRC ALERT14 High throughput bio-layer interferometry at Dundee
Amount £362,000 (GBP)
Funding ID BB/M012425/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2015 
End 01/2016
 
Description BBSRC EASTBIO Doctoral Training Partnership PhD Studentship
Amount £99,000 (GBP)
Funding ID BB/J01446X/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2014 
End 09/2018
 
Description BBSRC/Dundee College of Life Sciences (CLS) PhD Studentship
Amount £99,000 (GBP)
Organisation University of Dundee 
Sector Academic/University
Country United Kingdom
Start 09/2013 
End 08/2017
 
Description BBSRC/Dundee College of Life Sciences (CLS) PhD Studentship
Amount £24,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 04/2014 
End 09/2015
 
Description CAPES/Dundee PhD Studentship
Amount £63,000 (GBP)
Funding ID 7148-14-3 
Organisation Government of Brazil 
Department Coordination of Higher Education Personnel Training (CAPES)
Sector Public
Country Brazil
Start 03/2015 
End 03/2019
 
Description Dundee College of Life Sciences (CLS) PhD Studentship
Amount £64,000 (GBP)
Organisation University of Dundee 
Department College of Life Sciences
Sector Academic/University
Country United Kingdom
Start 10/2014 
End 04/2018
 
Description EC Horizon 2020 - Marie Sklodowska Curie Individual Fellowship
Amount € 183,000 (EUR)
Funding ID 705705 Anchor E3s 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2016 
End 08/2018
 
Description EC Horizon 2020 - Marie Sklodowska Curie Individual Fellowship
Amount € 183,000 (EUR)
Funding ID 655516 Bump-BET 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2015 
End 10/2017
 
Description ERC Starting Grant: DrugE3CRL
Amount € 1,500,000 (EUR)
Funding ID ERC Starting Grant 311460 DrugE3CRLs 
Organisation European Research Council (ERC) 
Sector Public
Country Belgium
Start 05/2013 
End 04/2018
 
Description Foundation BLANCEFLOR Boncompagni-Ludovisi Fellowship
Amount 120,000 kr (SEK)
Organisation Foundation Blanceflor Boncompagni Ludovisi, née Bildt 
Sector Academic/University
Country Sweden
Start 10/2015 
End 09/2016
 
Description MIUR Messaggeri della Conoscenza - Drug Discovery
Amount € 40,000 (EUR)
Funding ID ID 497 - Drug Discovery 
Organisation Italian Ministry of Education, Universities and Research 
Sector Public
Country Italy
Start 07/2013 
End 11/2014
 
Description Marie Curie Intra-European Fellowships for Career Development (IEF)
Amount € 200,000 (EUR)
Funding ID EU FP7-PEOPLE-2012-IEF 328030 orthoPROTACS 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 04/2013 
End 04/2015
 
Description Portuguese FCT Studentship
Amount € 132,000 (EUR)
Funding ID SFRH/BD/101598/2014 
Organisation Government of the Portugese Republic 
Department Foundation of Science and Technology (FCT)
Sector Public
Country Portugal
Start 04/2015 
End 04/2019
 
Description Portuguese FCT Studentship
Amount £107,977 (GBP)
Funding ID SFRH/BD/92417/2013 
Organisation Government of the Portugese Republic 
Department Foundation of Science and Technology (FCT)
Sector Public
Country Portugal
Start 05/2014 
End 05/2018
 
Description Research collaboration with Boehringer Ingelheim
Amount £0 (GBP)
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start 12/2016 
 
Description Research collaboration with industry
Amount £0 (GBP)
Organisation Nurix Inc 
Sector Private
Country United States
Start 09/2017 
 
Description Wellcome Trust 4 years PhD studentship
Amount £151,392 (GBP)
Funding ID 102398/Z/13/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2013 
End 06/2017
 
Title MZ1 
Description Description: (+)-JQ1 based PROTAC that selectively degrades BRD4 in cells Chemical Name: (2S,4R)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)- 4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Purity: =98% (HPLC) Biological Activity Cell penetrant Proteolysis Targeting Chimera (PROTAC) compound based on (+)-JQ1 (Cat.No. 4499) conjugated to a von Hippel-Lindau (VHL) ligand. Retains high affinity for BRD2, BRD3 and BRD4 bromodomains (Kd = 13-60 nM) but induces preferential degradation of BRD4 over BRD2 and BRD3 (DC50 values for degradation of BRD4 are 8 and 23 nM in H661 and H838 cells, respectively). Exhibits potent cytotoxicity and antiproliferative effects in AML cell lines (pEC50 = 7.6 in Mv4;11 cells). Negative control cis MZ 1 also available. PROTACs are bi-functional small molecules that harness the ubiquitin/proteasome system (UPS) to selectively and catalytically remove target proteins from cells. 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact References are publications that support the products' biological activity. Zengerle et al (2015) Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS.Chem.Biol 10 1770 PMID: 26035625 Gadd et al (2017) Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat.Chem.Biol. PMID: 28288108 Wurz et al (2017) A " click chemistry platform" for the rapid synthesis of bispecific molecules for inducing protein degradation. J.Med.Chem. PMID: 28378579 February 26, 2018, Sansam et al.; Genes & Dev. 2018. 32: 224-229 doi: 10.1101/gad.306464.117 
URL https://www.tocris.com/products/mz-1_6154
 
Title TC AC 28 
Description Description: High affinity BET bromodomain ligand Chemical Name: 6-(1H-Indol-4-yl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetic acid methyl ester Purity: =98% (HPLC) Biological Activity High affinity BET bromodomain ligand (Kd values are 40 and 800 nM for Brd2(2) and Brd2(1), respectively). Exhibits 20-fold selectively for the second over the first bromodomain. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact unknown 
URL https://www.tocris.com/products/tc-ac-28_6105
 
Title VHL inhibitor VH298: a new chemical probe of hypoxia signaling 
Description Chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs) activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities and off-target effects. Here we disclose VH298, a potent VHL inhibitor that stabilizes HIF-a and elicits a hypoxic response via a different mechanism, that is the blockade of the VHL:HIF-a protein-protein interaction downstream of HIF-a hydroxylation by PHD enzymes. We show that VH298 engages with high affinity and specificity with VHL as its only major cellular target, leading to selective on-target accumulation of hydroxylated HIF-a in a concentration- and time-dependent fashion in different cell lines, with subsequent upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a high-quality chemical probe of the HIF signalling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signalling. Description: High-affinity inhibitor of VHL Chemical Name: (2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Purity: =98% (HPLC) 
Type Of Material Technology assay or reagent 
Year Produced 2016 
Provided To Others? Yes  
Impact • Highlighted in Drug Discovery Today • Highlighted in ScienceDaily; Distributed by Tocris: 
URL http://www.chemicalprobes.org/vh298
 
Title chemical biology PROTAC approach to small-molecule induced target protein degradation 
Description Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases Patent Application No. GB 1521858.9 & GB 1504314.4 (Priority Date: March 13, 2015) PCT HGF Ref. P227094WO / FE (filing date March 14, 2016) WO 2016/146985 (International publication date September 22, 2016) 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact Paper published in 2014 ACS Chem Biol 
URL http://www.chemicalprobes.org/mz1
 
Title chemical genetics bump-and-hole approach to engineer controlled selectivity of BET bromodomain inhibitors 
Description compounds related to patent Enzyme Function Probes Patent Application No. 1320994.5 & 1401001.1 (Priority Date: 28 Nov 2013) 
Type Of Material Technology assay or reagent 
Year Produced 2014 
Provided To Others? Yes  
Impact paper just published in Science impact to see full realization in due course 
URL http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli/news/just-published-science-our-paper-describi...
 
Title cis MZ1 
Description Description: Negative Control for MZ1 Chemical Name: (2S,4S)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)- 4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Purity: =98% (HPLC) Biological Activity Negative Control for MZ1 (Cat.No. 6154). Exhibits no significant VHL binding affinity. 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact External Portal Information Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of MZ 1 is reviewed on the chemical probes website. 
URL https://www.tocris.com/products/cis-mz-1_6155
 
Description BioNMR collaborative project 261863 proposal no. BIO-NMR-00211 entitled: Structural modelling and dynamics of the Bromodomain Adjacent to Zinc finger domain containing protein 2B bromodomain 
Organisation Utrecht University
Country Netherlands 
Sector Academic/University 
PI Contribution Purified proteins to be used in NMR spectroscopic studies and binding assyas, and provided intellectual input
Collaborator Contribution Provided access to NMR facility and provided intellectual input and expertise
Impact 13. Ferguson, F.M., Dias, D.M., Rodrigues, J.P.G.L.M., Wienk, H., Boelens, R., Bonvin, A.M.J.J., Abell, C., Ciulli, A.* Binding hotspots of BAZ2B bromodomain: histone interaction revealed by solution NMR driven docking. Biochemistry, 2014, 53(42), 6706-6716.
Start Year 2013
 
Description BioNMR collaborative project BIO-NMR-00169 entitled: Targeting and characterising multi-protein complexes in Fragment-based drug discovery. Small molecules binding to VHL E3 Ubiquitin Ligase and protein binding partners studied by NMR spectroscopy. 
Organisation Utrecht University
Country Netherlands 
Sector Academic/University 
PI Contribution purified protein samples for NMR spectroscopic studies and provided intellectual input
Collaborator Contribution provide access to NMR instrumentation and facilities and provided intellectual input
Impact multi-disciplinary collaboration, involving NMR spectroscopy, biophysics, protein purification and characterization and drug discovery. Dias, D.M., Ciulli, A.* NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. Prog Biophys Mol Biol, 2014, 116(2-3), 101-112
Start Year 2013
 
Description Chemoproteomics of native protein complexes 
Organisation GlaxoSmithKline (GSK)
Department Cellzome Ltd
Country Germany 
Sector Private 
PI Contribution We provided Cellzome with compounds to be used in chemoproteomics studies to recruit native E3 Ubiquitin ligase protein complexes
Collaborator Contribution They performed chemoprotemics studies with our compounds, involving pull-down assays from cell lysates and mass spectrometric measurements to assess composition of recruited proteins and binding affinities of compounds
Impact Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198. Galdeano, Julianty et al. under revision
Start Year 2011
 
Description Ion mobility mass spectrometry to interrogate the structure and assembly of multisubunit protein complexes 
Organisation University of Antwerp
Department Department of Chemistry
Country Belgium 
Sector Academic/University 
PI Contribution We expressed and purified component subunits of the SOCS2-CRL E3 ligases assembled into specific complexes and provided the samples to the collaborator (Prof. Frank Sobott research team)
Collaborator Contribution They performed native nanoelectrospray ionization mass spectrometry and traveling wave ion mobility MS experiments on our samples and analyzed data.
Impact Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.
Start Year 2014
 
Description PROTAC collaboration with Boehringer Ingelheim (confidential) 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution drug discovery research
Collaborator Contribution drug discovery research
Impact confidential
Start Year 2016
 
Description Research collaboration with Industry (confidential) 
Organisation Nurix Inc
Country United States 
Sector Private 
PI Contribution drug discovery research
Collaborator Contribution drug discovery research
Impact no outcomes yet
Start Year 2017
 
Title DERIVATIVES OF 1-[(CYCLOPENTYL OR 2-PYRROLIDINYL)CARBONYLAMINOMETHYL]-4-(1,3-THIAZOL-5-YL) BENZENE WHICH ARE USEFUL FOR THE TREATMENT OF PROLIFERATIVE, AUTOIMMUNE OR INFLAMMATORY DISEASES 
Description There is provided novel small molecule E3 ubiquitin ligase protein binding ligand compounds, having utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for the preparation thereof, and use in medicine. There is particularly provided PROTACs which bind to a protein within the bromo- and Extra-terminal (BET) family of proteins, and especially to PROTACs including novel small molecule E3 ubiquitin ligase protein binding ligand compounds which selectively induce degradation of the BRD4 protein within the bromodomain of the BET family of proteins. 
IP Reference WO2016146985 
Protection Patent application published
Year Protection Granted 2016
Licensed Commercial In Confidence
Impact Impact yet to be realised.
 
Company Name AMPHISTA THERAPEUTICS LIMITED 
Description Amphista Therapeutics is a University of Dundee spin off company that is developing targeted protein degradation platforms 
Year Established 2017 
Impact commercial in confidence
 
Description Alessio delivers the course Drug Discovery to the Dept. of Pharmaceutical Chemistry at the University of Messina, under the realm of the new MIUR-funded programme Messaggeri della Conoscenza 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Taught a course in Drug Discovery which sparked questions, discussions and further interaction. Hosted 4 selected students in my laboratory the following year, and disseminated all activities, also in the form of a video publicly accessible online

Students, teachers and public in Italy more aware of the important of exchange programmes between Italy and UK
Year(s) Of Engagement Activity 2013
URL http://www.youtube.com/watch?v=GxrQwJO9HB8
 
Description Carles Galdeano (Ciulli Lab) to attend the 65th Lindau Nobel Laureate Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Carles Galdeano of the Ciulli Group participated in the 65th Lindau Nobel Laureate Meeting, that was held from 28 June to 3 July 2015, in Lindau, Germany. The annual Lindau Nobel Laureate Meetings provide a globally recognised forum for the transfer of knowledge between generations of scientists. This interdisciplinary meeting, brings together Nobel Laureates and the next generation of talented scientists from the field of physiology and medicine, physics and chemistry to inspire and motivate Nobel Laureates and international "best talents".

Lectures of Nobel Laureates reflect current scientific topics and present relevant fields of research of the FUTURE. In panel discussions, seminars and during the various events of the social programme, young researchers nominated by a worldwide network of academic partners interact with Nobel Laureates. The meetings of Nobel Laureates in chemistry, physiology or medicine and in physics have been held since 1951. 70 Nobel Laureates and 672 selected early-career researchers from 88 countries will participate in the 2015 meeting.
Year(s) Of Engagement Activity 2015
URL http://www.lifesci.dundee.ac.uk/news/2015/apr/15/carles-galdeano-ciulli-lab-attend-65th-lindau-nobel...
 
Description Media press release: Bump-and-hole approach brings protein breakthrough 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Media press release covering my laboratory recent article published in Science

After this press release, I have received a notable number of emails from other colleagues and friends to congratulate us with our achievement but also to tell me that they read the press release and this stimulated their interest in learning more about the topic of epigenetics and small molecule chemical biology and drug discovery. Many individuals have already contacted me to make requests for reagents, and many companies interested in this area have also approached me to express their willingness and interest to collaborate with us.

see:
http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx
http://www.lifesci.dundee.ac.uk/news/2014/oct/22/ciulli-labs-bump-and-hole-approach-leads-protein-breakthrough
Year(s) Of Engagement Activity 2014
URL http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx
 
Description Participation at the CLS Open Doors Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Our Institute Postdocs, PhD students, Support Staff, Facility Heads and PIs organized the Dundee College of Life Sceinces CLS Open Doors Day with great success on Saturday 8 November. Julianty Juliant, PhD student in my laboratory, participated.


We had over 400 people between 10am and 4pm and most of them stayed for over 2 hours. There's been amazing feedback and notes of thanks from members of the public, as well as requests from parent and kids asking us to visit their schools.
The most glowing praise was for our scientist/participants:- one lady summarises the main gist of the feedback by saying she found "the scientists just wonderful in their enthusiasm and explanations of the research they are conducting."
Year(s) Of Engagement Activity 2014
URL http://www.lifesci.dundee.ac.uk/news/2014/nov/10/well-done-and-thank-you-everyone-who-participated-o...